Literature DB >> 12843016

Widespread pyrazinamide-resistant Mycobacterium tuberculosis family in a low-incidence setting.

Dao Nguyen1, Paul Brassard, Jennifer Westley, Louise Thibert, Melanie Proulx, Kevin Henry, Kevin Schwartzman, Dick Menzies, Marcel A Behr.   

Abstract

An unusually high prevalence of pyrazinamide (PZA) monoresistance in Mycobacterium tuberculosis has been observed in Quebec. In the absence of a recognized outbreak, we hypothesized that these isolates most likely represented reactivation of an old endemic strain in this low-incidence area. A case-control study of 77 PZA-resistant isolates with a specific Quebec mutation and 253 PZA-susceptible control M. tuberculosis isolates was undertaken. By molecular analysis, all 77 case isolates shared a unique mutation profile in the pncA gene which was not present in control isolates. While control isolates manifested diverse IS6110 restriction fragment length polymorphism (RFLP) patterns, spoligotypes, and major genetic groups, case isolates had similar but nonidentical IS6110 RFLP patterns, had common spoligotypes, and were confined to one major genetic group, suggesting a common clonal ancestor. By epidemiologic and geographic analyses, however, there were no significant differences between the cases and the controls. We conclude that a clonally related family of PZA-monoresistant M. tuberculosis isolates in Quebec represents historic rather than recent transmission.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843016      PMCID: PMC165272          DOI: 10.1128/JCM.41.7.2878-2883.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  41 in total

1.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

2.  DNA restriction fragment analysis to define an extended cluster of tuberculosis in homeless men and their associates.

Authors:  B Dwyer; K Jackson; K Raios; A Sievers; E Wilshire; B Ross
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

3.  Microevolution of the direct repeat region of Mycobacterium tuberculosis: implications for interpretation of spoligotyping data.

Authors:  R M Warren; E M Streicher; S L Sampson; G D van der Spuy; M Richardson; D Nguyen; M A Behr; T C Victor; P D van Helden
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

4.  Molecular approach to identifying route of transmission of tuberculosis in the community.

Authors:  A Genewein; A Telenti; C Bernasconi; C Mordasini; S Weiss; A M Maurer; H L Rieder; K Schopfer; T Bodmer
Journal:  Lancet       Date:  1993-10-02       Impact factor: 79.321

5.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.

Authors:  A Scorpio; Y Zhang
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

6.  Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection.

Authors:  P M Small; R W Shafer; P C Hopewell; S P Singh; M J Murphy; E Desmond; M F Sierra; G K Schoolnik
Journal:  N Engl J Med       Date:  1993-04-22       Impact factor: 91.245

7.  Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods.

Authors:  D Alland; G E Kalkut; A R Moss; R A McAdam; J A Hahn; W Bosworth; E Drucker; B R Bloom
Journal:  N Engl J Med       Date:  1994-06-16       Impact factor: 91.245

8.  An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.

Authors:  C L Daley; P M Small; G F Schecter; G K Schoolnik; R A McAdam; W R Jacobs; P C Hopewell
Journal:  N Engl J Med       Date:  1992-01-23       Impact factor: 91.245

9.  Radiometric selective inhibition tests for differentiation of Mycobacterium tuberculosis, Mycobacterium bovis, and other mycobacteria.

Authors:  W M Gross; J E Hawkins
Journal:  J Clin Microbiol       Date:  1985-04       Impact factor: 5.948

10.  The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods.

Authors:  P M Small; P C Hopewell; S P Singh; A Paz; J Parsonnet; D C Ruston; G F Schecter; C L Daley; G K Schoolnik
Journal:  N Engl J Med       Date:  1994-06-16       Impact factor: 91.245

View more
  11 in total

1.  Sensitivities and specificities of spoligotyping and mycobacterial interspersed repetitive unit-variable-number tandem repeat typing methods for studying molecular epidemiology of tuberculosis.

Authors:  Allison N Scott; Dick Menzies; Terry-Nan Tannenbaum; Louise Thibert; Robert Kozak; Lawrence Joseph; Kevin Schwartzman; Marcel A Behr
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

2.  Spoligotype signatures in the Mycobacterium tuberculosis complex.

Authors:  E M Streicher; T C Victor; G van der Spuy; C Sola; N Rastogi; P D van Helden; R M Warren
Journal:  J Clin Microbiol       Date:  2006-10-25       Impact factor: 5.948

3.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

4.  Outbreak of pyrazinamide-monoresistant tuberculosis identified using genotype cluster and social media analysis.

Authors:  T A Thomas; S K Heysell; E R Houpt; J L Moore; S J Keller
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

5.  Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA.

Authors:  David C Alexander; Jennifer H Ma; Jennifer L Guthrie; Joanne Blair; Pam Chedore; Frances B Jamieson
Journal:  J Clin Microbiol       Date:  2012-08-15       Impact factor: 5.948

6.  Genomic characterization of an endemic Mycobacterium tuberculosis strain: evolutionary and epidemiologic implications.

Authors:  Dao Nguyen; Paul Brassard; Dick Menzies; Louise Thibert; Rob Warren; Serge Mostowy; Marcel Behr
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

7.  Signatures of Selection at Drug Resistance Loci in Mycobacterium tuberculosis.

Authors:  Tatum D Mortimer; Alexandra M Weber; Caitlin S Pepperell
Journal:  mSystems       Date:  2018-01-30       Impact factor: 6.496

8.  Genotypic characterization of drug resistant Mycobacterium tuberculosis in Quebec, 2002-2012.

Authors:  Joanna Spinato; Élyse Boivin; Émilie Bélanger-Trudelle; Huguette Fauchon; Cécile Tremblay; Hafid Soualhine
Journal:  BMC Microbiol       Date:  2016-07-26       Impact factor: 3.605

9.  Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation.

Authors:  Ola B Brynildsrud; Caitlin S Pepperell; Philip Suffys; Louis Grandjean; Johana Monteserin; Nadia Debech; Jon Bohlin; Kristian Alfsnes; John O-H Pettersson; Ingerid Kirkeleite; Fatima Fandinho; Marcia Aparecida da Silva; Joao Perdigao; Isabel Portugal; Miguel Viveiros; Taane Clark; Maxine Caws; Sarah Dunstan; Phan Vuong Khac Thai; Beatriz Lopez; Viviana Ritacco; Andrew Kitchen; Tyler S Brown; Dick van Soolingen; Mary B O'Neill; Kathryn E Holt; Edward J Feil; Barun Mathema; Francois Balloux; Vegard Eldholm
Journal:  Sci Adv       Date:  2018-10-17       Impact factor: 14.136

10.  Phenotypic and genotypic drug sensitivity of Mycobacterium tuberculosis complex isolated from South Omo Zone, Southern Ethiopia.

Authors:  Biniam Wondale; Girmay Medhin; Gemeda Abebe; Samuel Tolosa; Temesgen Mohammed; Takele Teklu; Rembert Pieper; Gobena Ameni
Journal:  Infect Drug Resist       Date:  2018-09-25       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.